ID   SACS_HUMAN              Reviewed;        4579 AA.
AC   Q9NZJ4; O94835; Q5T9J5; Q5T9J7; Q5T9J8; Q68DF5; Q6MZR4; Q8NBF9;
DT   21-FEB-2001, integrated into UniProtKB/Swiss-Prot.
DT   09-JAN-2007, sequence version 2.
DT   07-APR-2021, entry version 182.
DE   RecName: Full=Sacsin;
DE   AltName: Full=DnaJ homolog subfamily C member 29;
DE            Short=DNAJC29;
GN   Name=SACS; Synonyms=KIAA0730;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], VARIANT ALA-3369, AND INVOLVEMENT IN
RP   SACS.
RX   PubMed=10655055; DOI=10.1038/72769;
RA   Engert J.C., Berube P., Mercier J., Dore C., Lepage P., Ge B.,
RA   Bouchard J.-P., Mathieu J., Melancon S.B., Schalling M., Lander E.S.,
RA   Morgan K., Hudson T.J., Richter A.;
RT   "ARSACS, a spastic ataxia common in northeastern Quebec, is caused by
RT   mutations in a new gene encoding an 11.5-kb ORF.";
RL   Nat. Genet. 24:120-125(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057823; DOI=10.1038/nature02379;
RA   Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L.,
RA   Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E., Griffiths-Jones S.,
RA   Jones M.C., Keenan S.J., Oliver K., Scott C.E., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Andrews D.T., Ashwell R.I.S., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Bannerjee R., Barlow K.F., Bates K., Beasley H., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M., Clegg S.C.,
RA   Cobley V., Collins J.E., Corby N., Coville G.J., Deloukas P., Dhami P.,
RA   Dunham I., Dunn M., Earthrowl M.E., Ellington A.G., Faulkner L.,
RA   Frankish A.G., Frankland J., French L., Garner P., Garnett J.,
RA   Gilbert J.G.R., Gilson C.J., Ghori J., Grafham D.V., Gribble S.M.,
RA   Griffiths C., Hall R.E., Hammond S., Harley J.L., Hart E.A., Heath P.D.,
RA   Howden P.J., Huckle E.J., Hunt P.J., Hunt A.R., Johnson C., Johnson D.,
RA   Kay M., Kimberley A.M., King A., Laird G.K., Langford C.J., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Lloyd C., Loveland J.E., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S.,
RA   Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I., Pelan S.,
RA   Phillimore B., Porter K.M., Rice C.M., Searle S., Sehra H.K., Shownkeen R.,
RA   Skuce C.D., Smith M., Steward C.A., Sycamore N., Tester J., Thomas D.W.,
RA   Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Wilming L., Wray P.W., Wright M.W., Young L.,
RA   Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Beck S., Bentley D.R.,
RA   Rogers J., Ross M.T.;
RT   "The DNA sequence and analysis of human chromosome 13.";
RL   Nature 428:522-528(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 102-2438 (ISOFORM 1).
RC   TISSUE=Fetal liver, and Uterine endothelium;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 377-750 (ISOFORM 1).
RC   TISSUE=Astrocyte;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 3576-4579.
RC   TISSUE=Brain;
RX   PubMed=9872452; DOI=10.1093/dnares/5.5.277;
RA   Nagase T., Ishikawa K., Suyama M., Kikuno R., Miyajima N., Tanaka A.,
RA   Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XI. The
RT   complete sequences of 100 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 5:277-286(1998).
RN   [6]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [7]
RP   FUNCTION, SUBCELLULAR LOCATION, DOMAIN UBIQUITIN-LIKE, AND DOMAIN J.
RX   PubMed=19208651; DOI=10.1093/hmg/ddp067;
RA   Parfitt D.A., Michael G.J., Vermeulen E.G., Prodromou N.V., Webb T.R.,
RA   Gallo J.M., Cheetham M.E., Nicoll W.S., Blatch G.L., Chapple J.P.;
RT   "The ataxia protein sacsin is a functional co-chaperone that protects
RT   against polyglutamine-expanded ataxin-1.";
RL   Hum. Mol. Genet. 18:1556-1565(2009).
RN   [8]
RP   INVOLVEMENT IN SACS.
RX   PubMed=19529988; DOI=10.1007/s12031-009-9212-9;
RA   Bouhlal Y., El Euch-Fayeche G., Hentati F., Amouri R.;
RT   "A novel SACS gene mutation in a Tunisian family.";
RL   J. Mol. Neurosci. 39:333-336(2009).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1779 AND SER-4264, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [10]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-943, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1779, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-3435, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1779 AND SER-4264, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [15]
RP   STRUCTURE BY NMR OF 4306-4380.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of DnaJ domain of human KIAA0730 protein.";
RL   Submitted (OCT-2003) to the PDB data bank.
RN   [16]
RP   VARIANTS SACS ARG-1946 AND PRO-4074.
RX   PubMed=12873855; DOI=10.1001/archneur.60.7.982;
RA   El Euch-Fayache G., Lalani I., Amouri R., Turki I., Ouahchi K., Hung W.Y.,
RA   Belal S., Siddique T., Hentati F.;
RT   "Phenotypic features and genetic findings in sacsin-related autosomal
RT   recessive ataxia in Tunisia.";
RL   Arch. Neurol. 60:982-988(2003).
RN   [17]
RP   VARIANT SACS ASP-4549.
RX   PubMed=15156359; DOI=10.1007/s10048-004-0179-y;
RA   Richter A.M., Ozgul R.K., Poisson V.C., Topaloglu H.;
RT   "Private SACS mutations in autosomal recessive spastic ataxia of
RT   Charlevoix-Saguenay (ARSACS) families from Turkey.";
RL   Neurogenetics 5:165-170(2004).
RN   [18]
RP   VARIANT SACS ARG-3248.
RX   PubMed=14718708; DOI=10.1212/01.wnl.0000099371.14478.73;
RA   Ogawa T., Takiyama Y., Sakoe K., Mori K., Namekawa M., Shimazaki H.,
RA   Nakano I., Nishizawa M.;
RT   "Identification of a SACS gene missense mutation in ARSACS.";
RL   Neurology 62:107-109(2004).
RN   [19]
RP   VARIANT SACS CYS-2703.
RX   PubMed=16007637; DOI=10.1002/mds.20579;
RA   Criscuolo C., Sacca F., De Michele G., Mancini P., Combarros O.,
RA   Infante J., Garcia A., Banfi S., Filla A., Berciano J.;
RT   "Novel mutation of SACS gene in a Spanish family with autosomal recessive
RT   spastic ataxia.";
RL   Mov. Disord. 20:1358-1361(2005).
RN   [20]
RP   VARIANT SACS SER-1054.
RX   PubMed=15985586; DOI=10.1212/01.wnl.0000166031.91514.b3;
RA   Shimazaki H., Takiyama Y., Sakoe K., Ando Y., Nakano I.;
RT   "A phenotype without spasticity in sacsin-related ataxia.";
RL   Neurology 64:2129-2131(2005).
RN   [21]
RP   VARIANT [LARGE SCALE ANALYSIS] ILE-1795.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [22]
RP   VARIANT SACS PHE-308.
RX   PubMed=17290461; DOI=10.1002/mds.21365;
RA   Takado Y., Hara K., Shimohata T., Tokiguchi S., Onodera O., Nishizawa M.;
RT   "New mutation in the non-gigantic exon of SACS in Japanese siblings.";
RL   Mov. Disord. 22:748-749(2007).
RN   [23]
RP   VARIANT SACS SER-3653.
RX   PubMed=18398442; DOI=10.1038/ejhg.2008.58;
RA   Breckpot J., Takiyama Y., Thienpont B., Van Vooren S., Vermeesch J.R.,
RA   Ortibus E., Devriendt K.;
RT   "A novel genomic disorder: a deletion of the SACS gene leading to spastic
RT   ataxia of Charlevoix-Saguenay.";
RL   Eur. J. Hum. Genet. 16:1050-1054(2008).
RN   [24]
RP   VARIANT SACS PRO-802.
RX   PubMed=18484239; DOI=10.1007/s00415-008-0672-6;
RA   Kamada S., Okawa S., Imota T., Sugawara M., Toyoshima I.;
RT   "Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS): novel
RT   compound heterozygous mutations in the SACS gene.";
RL   J. Neurol. 255:803-806(2008).
RN   [25]
RP   VARIANT SACS LYS-1311.
RX   PubMed=17716690; DOI=10.1016/j.jns.2007.07.022;
RA   Ouyang Y., Segers K., Bouquiaux O., Wang F.C., Janin N., Andris C.,
RA   Shimazaki H., Sakoe K., Nakano I., Takiyama Y.;
RT   "Novel SACS mutation in a Belgian family with sacsin-related ataxia.";
RL   J. Neurol. Sci. 264:73-76(2008).
RN   [26]
RP   VARIANTS SACS TYR-168; GLN-2801 DEL; PRO-3481 AND GLN-4331.
RX   PubMed=18465152; DOI=10.1007/s10048-008-0131-7;
RA   Vermeer S., Meijer R.P., Pijl B.J., Timmermans J., Cruysberg J.R.,
RA   Bos M.M., Schelhaas H.J., van de Warrenburg B.P., Knoers N.V., Scheffer H.,
RA   Kremer B.;
RT   "ARSACS in the Dutch population: a frequent cause of early-onset cerebellar
RT   ataxia.";
RL   Neurogenetics 9:207-214(2008).
RN   [27]
RP   VARIANTS SACS LYS-201; PRO-556; ARG-991; PRO-1575; ARG-1587; SER-2032 DEL;
RP   GLN-2798; GLN-3636; PRO-3645; THR-3652; LYS-4343 AND THR-4508.
RX   PubMed=20876471; DOI=10.1212/wnl.0b013e3181f4d86c;
RA   Baets J., Deconinck T., Smets K., Goossens D., Van den Bergh P., Dahan K.,
RA   Schmedding E., Santens P., Rasic V.M., Van Damme P., Robberecht W.,
RA   De Meirleir L., Michielsens B., Del-Favero J., Jordanova A., De Jonghe P.;
RT   "Mutations in SACS cause atypical and late-onset forms of ARSACS.";
RL   Neurology 75:1181-1188(2010).
RN   [28]
RP   VARIANT ALA-3702.
RX   PubMed=23800155; DOI=10.1111/ene.12220;
RA   Gregianin E., Vazza G., Scaramel E., Boaretto F., Vettori A., Leonardi E.,
RA   Tosatto S.C., Manara R., Pegoraro E., Mostacciuolo M.L.;
RT   "A novel SACS mutation results in non-ataxic spastic paraplegia and
RT   peripheral neuropathy.";
RL   Eur. J. Neurol. 20:1486-1491(2013).
RN   [29]
RP   VARIANT SACS LYS-LEU-PRO-3118 INS.
RX   PubMed=27133561; DOI=10.1002/ajmg.a.37684;
RG   FORGE Canada Consortium;
RA   Armour C.M., Smith A., Hartley T., Chardon J.W., Sawyer S.,
RA   Schwartzentruber J., Hennekam R., Majewski J., Bulman D.E., Suri M.,
RA   Boycott K.M.;
RT   "Syndrome disintegration: Exome sequencing reveals that Fitzsimmons
RT   syndrome is a co-occurrence of multiple events.";
RL   Am. J. Med. Genet. A 170:1820-1825(2016).
RN   [30]
RP   VARIANT SER-3750.
RX   PubMed=31637422; DOI=10.1093/brain/awz291;
RG   Deciphering Developmental Disorders Study;
RA   Vaz F.M., McDermott J.H., Alders M., Wortmann S.B., Koelker S.,
RA   Pras-Raves M.L., Vervaart M.A.T., van Lenthe H., Luyf A.C.M., Elfrink H.L.,
RA   Metcalfe K., Cuvertino S., Clayton P.E., Yarwood R., Lowe M.P., Lovell S.,
RA   Rogers R.C., van Kampen A.H.C., Ruiter J.P.N., Wanders R.J.A.,
RA   Ferdinandusse S., van Weeghel M., Engelen M., Banka S.;
RT   "Mutations in PCYT2 disrupt etherlipid biosynthesis and cause a complex
RT   hereditary spastic paraplegia.";
RL   Brain 142:3382-3397(2019).
CC   -!- FUNCTION: Co-chaperone which acts as a regulator of the Hsp70 chaperone
CC       machinery and may be involved in the processing of other ataxia-linked
CC       proteins. {ECO:0000269|PubMed:19208651}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:19208651}.
CC       Note=Predominantly cytoplasmic, a small portion is present in the
CC       nucleus and also shows a partial mitochondrial overlap with the
CC       mitochondrial marker Hsp60.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9NZJ4-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9NZJ4-2; Sequence=VSP_022325;
CC   -!- TISSUE SPECIFICITY: Highly expressed in the central nervous system.
CC       Also found in skeletal muscle and at low levels in pancreas.
CC   -!- DOMAIN: The ubiquitin-like domain mediates interaction with the
CC       proteasome. {ECO:0000269|PubMed:19208651}.
CC   -!- DOMAIN: The J domain is functional and is shown to stimulate E.coli
CC       dnaK ATPase activity. {ECO:0000269|PubMed:19208651}.
CC   -!- DISEASE: Spastic ataxia Charlevoix-Saguenay type (SACS) [MIM:270550]: A
CC       neurodegenerative disease characterized by early-onset cerebellar
CC       ataxia, spasticity, retinal hypermyelination, pyramidal signs, and both
CC       axonal and demyelinating neuropathy with loss of sensory nerve
CC       conduction and reduced motor conduction velocities. Other features
CC       include dysarthria, distal muscle wasting, nystagmus, defect in
CC       conjugate pursuit ocular movements, retinal striation (from prominent
CC       retinal nerves) obscuring the retinal blood vessels in places, and the
CC       frequent presence of mitral valve prolapse.
CC       {ECO:0000269|PubMed:10655055, ECO:0000269|PubMed:12873855,
CC       ECO:0000269|PubMed:14718708, ECO:0000269|PubMed:15156359,
CC       ECO:0000269|PubMed:15985586, ECO:0000269|PubMed:16007637,
CC       ECO:0000269|PubMed:17290461, ECO:0000269|PubMed:17716690,
CC       ECO:0000269|PubMed:18398442, ECO:0000269|PubMed:18465152,
CC       ECO:0000269|PubMed:18484239, ECO:0000269|PubMed:19529988,
CC       ECO:0000269|PubMed:20876471, ECO:0000269|PubMed:27133561}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAC03486.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=CAH18265.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF193556; AAF31262.1; -; Genomic_DNA.
DR   EMBL; AL157766; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BX640926; CAE45964.1; -; mRNA.
DR   EMBL; CR749427; CAH18265.1; ALT_INIT; mRNA.
DR   EMBL; AK090599; BAC03486.1; ALT_INIT; mRNA.
DR   EMBL; AB018273; BAA34450.1; -; mRNA.
DR   CCDS; CCDS9300.2; -. [Q9NZJ4-1]
DR   RefSeq; NP_055178.3; NM_014363.5. [Q9NZJ4-1]
DR   PDB; 1IUR; NMR; -; A=4306-4380.
DR   PDB; 3O10; X-ray; 1.90 A; A/B/C/D=4440-4579.
DR   PDB; 5V44; X-ray; 1.56 A; A/B/C=89-336.
DR   PDB; 5V45; X-ray; 1.91 A; A/B=89-336.
DR   PDB; 5V46; X-ray; 1.80 A; A/B=89-336.
DR   PDB; 5VSX; X-ray; 2.10 A; A/B=2-85.
DR   PDB; 5VSZ; X-ray; 2.40 A; A/B=2-85.
DR   PDBsum; 1IUR; -.
DR   PDBsum; 3O10; -.
DR   PDBsum; 5V44; -.
DR   PDBsum; 5V45; -.
DR   PDBsum; 5V46; -.
DR   PDBsum; 5VSX; -.
DR   PDBsum; 5VSZ; -.
DR   BMRB; Q9NZJ4; -.
DR   SMR; Q9NZJ4; -.
DR   BioGRID; 117661; 28.
DR   IntAct; Q9NZJ4; 19.
DR   MINT; Q9NZJ4; -.
DR   STRING; 9606.ENSP00000371735; -.
DR   iPTMnet; Q9NZJ4; -.
DR   PhosphoSitePlus; Q9NZJ4; -.
DR   BioMuta; SACS; -.
DR   DMDM; 122066060; -.
DR   EPD; Q9NZJ4; -.
DR   jPOST; Q9NZJ4; -.
DR   MassIVE; Q9NZJ4; -.
DR   MaxQB; Q9NZJ4; -.
DR   PaxDb; Q9NZJ4; -.
DR   PeptideAtlas; Q9NZJ4; -.
DR   PRIDE; Q9NZJ4; -.
DR   ProteomicsDB; 83414; -. [Q9NZJ4-1]
DR   ProteomicsDB; 83415; -. [Q9NZJ4-2]
DR   Antibodypedia; 57260; 52 antibodies.
DR   Ensembl; ENST00000382292; ENSP00000371729; ENSG00000151835. [Q9NZJ4-1]
DR   Ensembl; ENST00000402364; ENSP00000385844; ENSG00000151835. [Q9NZJ4-2]
DR   GeneID; 26278; -.
DR   KEGG; hsa:26278; -.
DR   UCSC; uc001uon.3; human. [Q9NZJ4-1]
DR   CTD; 26278; -.
DR   DisGeNET; 26278; -.
DR   GeneCards; SACS; -.
DR   GeneReviews; SACS; -.
DR   HGNC; HGNC:10519; SACS.
DR   HPA; ENSG00000151835; Tissue enhanced (parathyroid).
DR   MalaCards; SACS; -.
DR   MIM; 270550; phenotype.
DR   MIM; 604490; gene.
DR   neXtProt; NX_Q9NZJ4; -.
DR   OpenTargets; ENSG00000151835; -.
DR   Orphanet; 98; Autosomal recessive spastic ataxia of Charlevoix-Saguenay.
DR   PharmGKB; PA34927; -.
DR   VEuPathDB; HostDB:ENSG00000151835.13; -.
DR   eggNOG; ENOG502QQPY; Eukaryota.
DR   GeneTree; ENSGT00390000016695; -.
DR   HOGENOM; CLU_000100_0_0_1; -.
DR   InParanoid; Q9NZJ4; -.
DR   OMA; VGEVFCY; -.
DR   OrthoDB; 1502266at2759; -.
DR   PhylomeDB; Q9NZJ4; -.
DR   TreeFam; TF331145; -.
DR   PathwayCommons; Q9NZJ4; -.
DR   BioGRID-ORCS; 26278; 20 hits in 995 CRISPR screens.
DR   ChiTaRS; SACS; human.
DR   EvolutionaryTrace; Q9NZJ4; -.
DR   GeneWiki; Sacsin; -.
DR   GenomeRNAi; 26278; -.
DR   Pharos; Q9NZJ4; Tbio.
DR   PRO; PR:Q9NZJ4; -.
DR   Proteomes; UP000005640; Chromosome 13.
DR   RNAct; Q9NZJ4; protein.
DR   Bgee; ENSG00000151835; Expressed in forebrain and 236 other tissues.
DR   ExpressionAtlas; Q9NZJ4; baseline and differential.
DR   Genevisible; Q9NZJ4; HS.
DR   GO; GO:0030424; C:axon; TAS:BHF-UCL.
DR   GO; GO:0070852; C:cell body fiber; TAS:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0030425; C:dendrite; TAS:BHF-UCL.
DR   GO; GO:0005739; C:mitochondrion; IDA:BHF-UCL.
DR   GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR   GO; GO:0051087; F:chaperone binding; IDA:UniProtKB.
DR   GO; GO:0030544; F:Hsp70 protein binding; IPI:BHF-UCL.
DR   GO; GO:0070628; F:proteasome binding; IPI:BHF-UCL.
DR   GO; GO:0090084; P:negative regulation of inclusion body assembly; IMP:BHF-UCL.
DR   GO; GO:0006457; P:protein folding; NAS:UniProtKB.
DR   Gene3D; 1.10.287.110; -; 1.
DR   Gene3D; 3.30.565.10; -; 1.
DR   InterPro; IPR001623; DnaJ_domain.
DR   InterPro; IPR036890; HATPase_C_sf.
DR   InterPro; IPR007842; HEPN_dom.
DR   InterPro; IPR036869; J_dom_sf.
DR   InterPro; IPR000626; Ubiquitin-like_dom.
DR   InterPro; IPR029071; Ubiquitin-like_domsf.
DR   Pfam; PF05168; HEPN; 1.
DR   Pfam; PF00240; ubiquitin; 1.
DR   SMART; SM00748; HEPN; 1.
DR   SUPFAM; SSF46565; SSF46565; 1.
DR   SUPFAM; SSF54236; SSF54236; 1.
DR   SUPFAM; SSF55874; SSF55874; 3.
DR   PROSITE; PS50076; DNAJ_2; 1.
DR   PROSITE; PS50910; HEPN; 1.
DR   PROSITE; PS50053; UBIQUITIN_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Chaperone; Cytoplasm;
KW   Disease variant; Neurodegeneration; Phosphoprotein; Reference proteome.
FT   CHAIN           1..4579
FT                   /note="Sacsin"
FT                   /id="PRO_0000097563"
FT   DOMAIN          9..84
FT                   /note="Ubiquitin-like"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00214"
FT   DOMAIN          4306..4393
FT                   /note="J"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00286"
FT   DOMAIN          4451..4567
FT                   /note="HEPN"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00105"
FT   MOD_RES         943
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         1779
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         2511
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9JLC8"
FT   MOD_RES         2516
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9JLC8"
FT   MOD_RES         3435
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         4261
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9JLC8"
FT   MOD_RES         4264
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         1..750
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_022325"
FT   VARIANT         168
FT                   /note="D -> Y (in SACS)"
FT                   /evidence="ECO:0000269|PubMed:18465152"
FT                   /id="VAR_064801"
FT   VARIANT         201
FT                   /note="T -> K (in SACS)"
FT                   /evidence="ECO:0000269|PubMed:20876471"
FT                   /id="VAR_064802"
FT   VARIANT         232
FT                   /note="N -> K (in dbSNP:rs2031640)"
FT                   /id="VAR_059716"
FT   VARIANT         308
FT                   /note="L -> F (in SACS)"
FT                   /evidence="ECO:0000269|PubMed:17290461"
FT                   /id="VAR_064803"
FT   VARIANT         556
FT                   /note="L -> P (in SACS; associated with Q-2798)"
FT                   /evidence="ECO:0000269|PubMed:20876471"
FT                   /id="VAR_064804"
FT   VARIANT         694
FT                   /note="A -> T (in dbSNP:rs17325713)"
FT                   /id="VAR_059717"
FT   VARIANT         802
FT                   /note="L -> P (in SACS)"
FT                   /evidence="ECO:0000269|PubMed:18484239"
FT                   /id="VAR_064805"
FT   VARIANT         991
FT                   /note="C -> R (in SACS)"
FT                   /evidence="ECO:0000269|PubMed:20876471"
FT                   /id="VAR_064806"
FT   VARIANT         1054
FT                   /note="F -> S (in SACS; atypical phenotype without
FT                   spasticity or hyperreflexia; dbSNP:rs137853019)"
FT                   /evidence="ECO:0000269|PubMed:15985586"
FT                   /id="VAR_064807"
FT   VARIANT         1311
FT                   /note="M -> K (in SACS)"
FT                   /evidence="ECO:0000269|PubMed:17716690"
FT                   /id="VAR_064808"
FT   VARIANT         1575
FT                   /note="R -> P (in SACS)"
FT                   /evidence="ECO:0000269|PubMed:20876471"
FT                   /id="VAR_064809"
FT   VARIANT         1587
FT                   /note="H -> R (in SACS)"
FT                   /evidence="ECO:0000269|PubMed:20876471"
FT                   /id="VAR_064810"
FT   VARIANT         1795
FT                   /note="M -> I (in a colorectal cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_035986"
FT   VARIANT         1946
FT                   /note="W -> R (in SACS; dbSNP:rs137853017)"
FT                   /evidence="ECO:0000269|PubMed:12873855"
FT                   /id="VAR_064811"
FT   VARIANT         2017
FT                   /note="K -> N (in dbSNP:rs35865691)"
FT                   /id="VAR_059718"
FT   VARIANT         2032
FT                   /note="Missing (in SACS)"
FT                   /evidence="ECO:0000269|PubMed:20876471"
FT                   /id="VAR_064812"
FT   VARIANT         2703
FT                   /note="R -> C (in SACS; dbSNP:rs780332615)"
FT                   /evidence="ECO:0000269|PubMed:16007637"
FT                   /id="VAR_064813"
FT   VARIANT         2798
FT                   /note="P -> Q (in SACS; associated with P-556;
FT                   dbSNP:rs140551762)"
FT                   /evidence="ECO:0000269|PubMed:20876471"
FT                   /id="VAR_064814"
FT   VARIANT         2801
FT                   /note="Missing (in SACS)"
FT                   /evidence="ECO:0000269|PubMed:18465152"
FT                   /id="VAR_064815"
FT   VARIANT         2958
FT                   /note="K -> R (in dbSNP:rs11839380)"
FT                   /id="VAR_059719"
FT   VARIANT         3118
FT                   /note="P -> PKLP (in SACS)"
FT                   /evidence="ECO:0000269|PubMed:27133561"
FT                   /id="VAR_076760"
FT   VARIANT         3248
FT                   /note="W -> R (in SACS; dbSNP:rs137853018)"
FT                   /evidence="ECO:0000269|PubMed:14718708"
FT                   /id="VAR_064816"
FT   VARIANT         3369
FT                   /note="V -> A (in dbSNP:rs17078605)"
FT                   /evidence="ECO:0000269|PubMed:10655055"
FT                   /id="VAR_010296"
FT   VARIANT         3481
FT                   /note="L -> P (in SACS)"
FT                   /evidence="ECO:0000269|PubMed:18465152"
FT                   /id="VAR_064817"
FT   VARIANT         3636
FT                   /note="R -> Q (in SACS; associated with T-3652;
FT                   dbSNP:rs281865119)"
FT                   /evidence="ECO:0000269|PubMed:20876471"
FT                   /id="VAR_064818"
FT   VARIANT         3645
FT                   /note="L -> P (in SACS)"
FT                   /evidence="ECO:0000269|PubMed:20876471"
FT                   /id="VAR_064819"
FT   VARIANT         3652
FT                   /note="P -> T (in SACS; associated with Q-3636;
FT                   dbSNP:rs201505036)"
FT                   /evidence="ECO:0000269|PubMed:20876471"
FT                   /id="VAR_064820"
FT   VARIANT         3653
FT                   /note="F -> S (in SACS)"
FT                   /evidence="ECO:0000269|PubMed:18398442"
FT                   /id="VAR_064821"
FT   VARIANT         3678
FT                   /note="P -> A (in dbSNP:rs17078601)"
FT                   /id="VAR_059720"
FT   VARIANT         3702
FT                   /note="T -> A (probable disease-associated variant found in
FT                   non-ataxic spastic paraplegia with peripheral neuropathy)"
FT                   /evidence="ECO:0000269|PubMed:23800155"
FT                   /id="VAR_069775"
FT   VARIANT         3750
FT                   /note="N -> S (found in a patient with spastic paraplegia;
FT                   unknown pathological significance; dbSNP:rs376188585)"
FT                   /evidence="ECO:0000269|PubMed:31637422"
FT                   /id="VAR_083891"
FT   VARIANT         4074
FT                   /note="A -> P (in SACS; dbSNP:rs137853016)"
FT                   /evidence="ECO:0000269|PubMed:12873855"
FT                   /id="VAR_064822"
FT   VARIANT         4217
FT                   /note="N -> D (in dbSNP:rs35799469)"
FT                   /id="VAR_059721"
FT   VARIANT         4331
FT                   /note="R -> Q (in SACS; dbSNP:rs773009784)"
FT                   /evidence="ECO:0000269|PubMed:18465152"
FT                   /id="VAR_064823"
FT   VARIANT         4343
FT                   /note="E -> K (in SACS; dbSNP:rs749383532)"
FT                   /evidence="ECO:0000269|PubMed:20876471"
FT                   /id="VAR_064824"
FT   VARIANT         4508
FT                   /note="K -> T (in SACS)"
FT                   /evidence="ECO:0000269|PubMed:20876471"
FT                   /id="VAR_064825"
FT   VARIANT         4549
FT                   /note="N -> D (in SACS; dbSNP:rs1178912631)"
FT                   /evidence="ECO:0000269|PubMed:15156359"
FT                   /id="VAR_064826"
FT   CONFLICT        730..750
FT                   /note="RPCTQLQLLNPERFARLIKEV -> FLFDEDSNGKLKMVAVLITSC (in
FT                   Ref. 4; BAC03486)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        812..832
FT                   /note="QTCVELIRLRIPSLVILDDES -> FLFDEDSNGKLKMVAVLITSC (in
FT                   Ref. 3; CAE45964)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1827
FT                   /note="G -> R (in Ref. 3; CAH18265)"
FT                   /evidence="ECO:0000305"
FT   HELIX           31..42
FT                   /evidence="ECO:0007744|PDB:5VSX"
FT   HELIX           46..48
FT                   /evidence="ECO:0007744|PDB:5VSX"
FT   STRAND          50..53
FT                   /evidence="ECO:0007744|PDB:5VSX"
FT   HELIX           64..67
FT                   /evidence="ECO:0007744|PDB:5VSX"
FT   STRAND          77..79
FT                   /evidence="ECO:0007744|PDB:5VSX"
FT   STRAND          89..91
FT                   /evidence="ECO:0007744|PDB:5V46"
FT   HELIX           96..106
FT                   /evidence="ECO:0007744|PDB:5V44"
FT   HELIX           112..123
FT                   /evidence="ECO:0007744|PDB:5V44"
FT   STRAND          127..134
FT                   /evidence="ECO:0007744|PDB:5V44"
FT   STRAND          140..144
FT                   /evidence="ECO:0007744|PDB:5V44"
FT   HELIX           146..151
FT                   /evidence="ECO:0007744|PDB:5V44"
FT   STRAND          155..162
FT                   /evidence="ECO:0007744|PDB:5V44"
FT   HELIX           166..172
FT                   /evidence="ECO:0007744|PDB:5V44"
FT   STRAND          175..177
FT                   /evidence="ECO:0007744|PDB:5V46"
FT   HELIX           193..199
FT                   /evidence="ECO:0007744|PDB:5V44"
FT   STRAND          205..209
FT                   /evidence="ECO:0007744|PDB:5V44"
FT   STRAND          211..215
FT                   /evidence="ECO:0007744|PDB:5V44"
FT   STRAND          227..232
FT                   /evidence="ECO:0007744|PDB:5V44"
FT   TURN            233..236
FT                   /evidence="ECO:0007744|PDB:5V44"
FT   HELIX           237..242
FT                   /evidence="ECO:0007744|PDB:5V44"
FT   HELIX           244..247
FT                   /evidence="ECO:0007744|PDB:5V44"
FT   HELIX           248..250
FT                   /evidence="ECO:0007744|PDB:5V44"
FT   STRAND          251..253
FT                   /evidence="ECO:0007744|PDB:5V44"
FT   HELIX           258..263
FT                   /evidence="ECO:0007744|PDB:5V44"
FT   STRAND          266..274
FT                   /evidence="ECO:0007744|PDB:5V44"
FT   HELIX           289..308
FT                   /evidence="ECO:0007744|PDB:5V44"
FT   STRAND          315..321
FT                   /evidence="ECO:0007744|PDB:5V44"
FT   STRAND          327..334
FT                   /evidence="ECO:0007744|PDB:5V44"
FT   HELIX           4307..4316
FT                   /evidence="ECO:0007744|PDB:1IUR"
FT   HELIX           4323..4335
FT                   /evidence="ECO:0007744|PDB:1IUR"
FT   TURN            4338..4340
FT                   /evidence="ECO:0007744|PDB:1IUR"
FT   STRAND          4341..4343
FT                   /evidence="ECO:0007744|PDB:1IUR"
FT   HELIX           4345..4365
FT                   /evidence="ECO:0007744|PDB:1IUR"
FT   STRAND          4369..4373
FT                   /evidence="ECO:0007744|PDB:1IUR"
FT   HELIX           4444..4461
FT                   /evidence="ECO:0007744|PDB:3O10"
FT   HELIX           4462..4464
FT                   /evidence="ECO:0007744|PDB:3O10"
FT   TURN            4465..4468
FT                   /evidence="ECO:0007744|PDB:3O10"
FT   HELIX           4470..4493
FT                   /evidence="ECO:0007744|PDB:3O10"
FT   HELIX           4502..4510
FT                   /evidence="ECO:0007744|PDB:3O10"
FT   HELIX           4514..4516
FT                   /evidence="ECO:0007744|PDB:3O10"
FT   HELIX           4519..4528
FT                   /evidence="ECO:0007744|PDB:3O10"
FT   TURN            4533..4537
FT                   /evidence="ECO:0007744|PDB:3O10"
FT   HELIX           4539..4541
FT                   /evidence="ECO:0007744|PDB:3O10"
FT   HELIX           4548..4551
FT                   /evidence="ECO:0007744|PDB:3O10"
FT   HELIX           4554..4576
FT                   /evidence="ECO:0007744|PDB:3O10"
SQ   SEQUENCE   4579 AA;  521126 MW;  84D7F36903F4518D CRC64;
     METKENRWVP VTVLPGCVGC RTVAALASWT VRDVKERIFA ETGFPVSEQR LWRGGRELSD
     WIKIGDLTSK NCHLFVNLQS KGLKGGGRFG QTTPPLVDFL KDILRRYPEG GQILKELIQN
     AEDAGATEVK FLYDETQYGT ETLWSKDMAP YQGPALYVYN NAVFTPEDWH GIQEIARSRK
     KDDPLKVGRF GIGFNSVYHI TDVPCIFSGD QIGMLDPHQT LFGPHESGQC WNLKDDSKEI
     SELSDQFAPF VGIFGSTKET FINGNFPGTF FRFPLRLQPS QLSSNLYNKQ KVLELFESFR
     ADADTVLLFL KSVQDVSLYV READGTEKLV FRVTSSESKA LKHERPNSIK ILGTAISNYC
     KKTPSNNITC VTYHVNIVLE EESTKDAQKT SWLVCNSVGG RGISSKLDSL ADELKFVPII
     GIAMPLSSRD DEAKGATSDF SGKAFCFLPL PPGEESSTGL PVHISGFFGL TDNRRSIKWR
     ELDQWRDPAA LWNEFLVMNV VPKAYATLIL DSIKRLEMEK SSDFPLSVDV IYKLWPEASK
     VKVHWQPVLE PLFSELLQNA VIYSISCDWV RLEQVYFSEL DENLEYTKTV LNYLQSSGKQ
     IAKVPGNVDA AVQLTAASGT TPVRKVTPAW VRQVLRKCAH LGCAEEKLHL LEFVLSDQAY
     SELLGLELLP LQNGNFVPFS SSVSDQDVIY ITSAEYPRSL FPSLEGRFIL DNLKPHLVAA
     LKEAAQTRGR PCTQLQLLNP ERFARLIKEV MNTFWPGREL IVQWYPFDEN RNHPSVSWLK
     MVWKNLYIHF SEDLTLFDEM PLIPRTILEE GQTCVELIRL RIPSLVILDD ESEAQLPEFL
     ADIVQKLGGF VLKKLDASIQ HPLIKKYIHS PLPSAVLQIM EKMPLQKLCN QITSLLPTHK
     DALRKFLASL TDSSEKEKRI IQELAIFKRI NHSSDQGISS YTKLKGCKVL HHTAKLPADL
     RLSISVIDSS DEATIRLANM LKIEQLKTTS CLKLVLKDIE NAFYSHEEVT QLMLWVLENL
     SSLKNENPNV LEWLTPLKFI QISQEQMVSA GELFDPDIEV LKDLFCNEEG TYFPPSVFTS
     PDILHSLRQI GLKNEASLKE KDVVQVAKKI EALQVGACPD QDVLLKKAKT LLLVLNKNHT
     LLQSSEGKMT LKKIKWVPAC KERPPNYPGS LVWKGDLCNL CAPPDMCDVG HAILIGSSLP
     LVESIHVNLE KALGIFTKPS LSAVLKHFKI VVDWYSSKTF SDEDYYQFQH ILLEIYGFMH
     DHLNEGKDSF RALKFPWVWT GKKFCPLAQA VIKPIHDLDL QPYLHNVPKT MAKFHQLFKV
     CGSIEELTSD HISMVIQKIY LKSDQDLSEQ ESKQNLHLML NIIRWLYSNQ IPASPNTPVP
     IHHSKNPSKL IMKPIHECCY CDIKVDDLND LLEDSVEPII LVHEDIPMKT AEWLKVPCLS
     TRLINPENMG FEQSGQREPL TVRIKNILEE YPSVSDIFKE LLQNADDANA TECSFLIDMR
     RNMDIRENLL DPGMAACHGP ALWSFNNSQF SDSDFVNITR LGESLKRGEV DKVGKFGLGF
     NSVYHITDIP IIMSREFMIM FDPNINHISK HIKDKSNPGI KINWSKQQKR LRKFPNQFKP
     FIDVFGCQLP LTVEAPYSYN GTLFRLSFRT QQEAKVSEVS STCYNTADIY SLVDEFSLCG
     HRLIIFTQSV KSMYLKYLKI EETNPSLAQD TVIIKKKSCS SKALNTPVLS VLKEAAKLMK
     TCSSSNKKLP SDEPKSSCIL QITVEEFHHV FRRIADLQSP LFRGPDDDPA ALFEMAKSGQ
     SKKPSDELSQ KTVECTTWLL CTCMDTGEAL KFSLSESGRR LGLVPCGAVG VQLSEIQDQK
     WTVKPHIGEV FCYLPLRIKT GLPVHINGCF AVTSNRKEIW KTDTKGRWNT TFMRHVIVKA
     YLQVLSVLRD LATSGELMDY TYYAVWPDPD LVHDDFSVIC QGFYEDIAHG KGKELTKVFS
     DGSTWVSMKN VRFLDDSILK RRDVGSAAFK IFLKYLKKTG SKNLCAVELP SSVKLGFEEA
     GCKQILLENT FSEKQFFSEV FFPNIQEIEA ELRDPLMIFV LNEKVDEFSG VLRVTPCIPC
     SLEGHPLVLP SRLIHPEGRV AKLFDIKDGR FPYGSTQDYL NPIILIKLVQ LGMAKDDILW
     DDMLERAVSV AEINKSDHVA ACLRSSILLS LIDEKLKIRD PRAKDFAAKY QTIRFLPFLT
     KPAGFSLDWK GNSFKPETMF AATDLYTAEH QDIVCLLQPI LNENSHSFRG CGSVSLAVKE
     FLGLLKKPTV DLVINQLKEV AKSVDDGITL YQENITNACY KYLHEALMQN EITKMSIIDK
     LKPFSFILVE NAYVDSEKVS FHLNFEAAPY LYQLPNKYKN NFRELFETVG VRQSCTVEDF
     ALVLESIDQE RGTKQITEEN FQLCRRIISE GIWSLIREKK QEFCEKNYGK ILLPDTNLML
     LPAKSLCYND CPWIKVKDTT VKYCHADIPR EVAVKLGAVP KRHKALERYA SNVCFTTLGT
     EFGQKEKLTS RIKSILNAYP SEKEMLKELL QNADDAKATE ICFVFDPRQH PVDRIFDDKW
     APLQGPALCV YNNQPFTEDD VRGIQNLGKG TKEGNPYKTG QYGIGFNSVY HITDCPSFIS
     GNDILCIFDP HARYAPGATS ISPGRMFRDL DADFRTQFSD VLDLYLGTHF KLDNCTMFRF
     PLRNAEMAKV SEISSVPASD RMVQNLLDKL RSDGAELLMF LNHMEKISIC EIDKSTGALN
     VLYSVKGKIT DGDRLKRKQF HASVIDSVTK KRQLKDIPVQ QITYTMDTED SEGNLTTWLI
     CNRSGFSSME KVSKSVISAH KNQDITLFPR GGVAACITHN YKKPHRAFCF LPLSLETGLP
     FHVNGHFALD SARRNLWRDD NGVGVRSDWN NSLMTALIAP AYVELLIQLK KRYFPGSDPT
     LSVLQNTPIH VVKDTLKKFL SFFPVNRLDL QPDLYCLVKA LYNCIHEDMK RLLPVVRAPN
     IDGSDLHSAV IITWINMSTS NKTRPFFDNL LQDELQHLKN ADYNITTRKT VAENVYRLKH
     LLLEIGFNLV YNCDETANLY HCLIDADIPV SYVTPADIRS FLMTFSSPDT NCHIGKLPCR
     LQQTNLKLFH SLKLLVDYCF KDAEENEIEV EGLPLLITLD SVLQTFDAKR PKFLTTYHEL
     IPSRKDLFMN TLYLKYSNIL LNCKVAKVFD ISSFADLLSS VLPREYKTKS CTKWKDNFAS
     ESWLKNAWHF ISESVSVKED QEETKPTFDI VVDTLKDWAL LPGTKFTVSA NQLVVPEGDV
     LLPLSLMHIA VFPNAQSDKV FHALMKAGCI QLALNKICSK DSAFVPLLSC HTANIESPTS
     ILKALHYMVQ TSTFRAEKLV ENDFEALLMY FNCNLNHLMS QDDIKILKSL PCYKSISGRY
     VSIGKFGTCY VLTKSIPSAE VEKWTQSSSS AFLEEKIHLK ELYEVIGCVP VDDLEVYLKH
     LLPKIENLSY DAKLEHLIYL KNRLSSAEEL SEIKEQLFEK LESLLIIHDA NSRLKQAKHF
     YDRTVRVFEV MLPEKLFIPN DFFKKLEQLI KPKNHVTFMT SWVEFLRNIG LKYILSQQQL
     LQFAKEISVR ANTENWSKET LQNTVDILLH HIFQERMDLL SGNFLKELSL IPFLCPERAP
     AEFIRFHPQY QEVNGTLPLI KFNGAQVNPK FKQCDVLQLL WTSCPILPEK ATPLSIKEQE
     GSDLGPQEQL EQVLNMLNVN LDPPLDKVIN NCRNICNITT LDEEMVKTRA KVLRSIYEFL
     SAEKREFRFQ LRGVAFVMVE DGWKLLKPEE VVINLEYESD FKPYLYKLPL ELGTFHQLFK
     HLGTEDIIST KQYVEVLSRI FKNSEGKQLD PNEMRTVKRV VSGLFRSLQN DSVKVRSDLE
     NVRDLALYLP SQDGRLVKSS ILVFDDAPHY KSRIQGNIGV QMLVDLSQCY LGKDHGFHTK
     LIMLFPQKLR PRLLSSILEE QLDEETPKVC QFGALCSLQG RLQLLLSSEQ FITGLIRIMK
     HENDNAFLAN EEKAIRLCKA LREGLKVSCF EKLQTTLRVK GFNPIPHSRS ETFAFLKRFG
     NAVILLYIQH SDSKDINFLL ALAMTLKSAT DNLISDTSYL IAMLGCNDIY RIGEKLDSLG
     VKYDSSEPSK LELPMPGTPI PAEIHYTLLM DPMNVFYPGE YVGYLVDAEG GDIYGSYQPT
     YTYAIIVQEV EREDADNSSF LGKIYQIDIG YSEYKIVSSL DLYKFSRPEE SSQSRDSAPS
     TPTSPTEFLT PGLRSIPPLF SGRESHKTSS KHQSPKKLKV NSLPEILKEV TSVVEQAWKL
     PESERKKIIR RLYLKWHPDK NPENHDIANE VFKHLQNEIN RLEKQAFLDQ NADRASRRTF
     STSASRFQSD KYSFQRFYTS WNQEATSHKS ERQQQNKEKC PPSAGQTYSQ RFFVPPTFKS
     VGNPVEARRW LRQARANFSA ARNDLHKNAN EWVCFKCYLS TKLALIAADY AVRGKSDKDV
     KPTALAQKIE EYSQQLEGLT NDVHTLEAYG VDSLKTRYPD LLPFPQIPND RFTSEVAMRV
     MECTACIIIK LENFMQQKV
//
